灵麦快讯LMLB122 【洞察】只有两个药？ 胶质瘤领域药物的前世今生
欢迎分享，转载有版权, 快快登录 lingmed.net/reports 下载全文吧！
本周灵麦医药推荐一篇专题市场分析报告 - 胶质瘤领域经典药物历史销量及未来潜力项目预测
神经胶质瘤（Glioma）是最常见的原发性脑瘤，简称胶质瘤，指的是起源于大脑和脊髓胶质细胞癌变的各类肿瘤统称，包括胶质母细胞瘤（Glioblastoma multiforme, GBM），星型细胞瘤，少支胶质瘤与室管膜瘤等。在原发性恶性中枢神经系统肿瘤中，胶质母细胞瘤(GBM, WHO Ⅳ级)的发病率最高，占了46.1%。近30年来，原发性恶性脑肿瘤发病率逐年递增，年增长率为1%～2%，在老年人群中尤为明显。然而，现阶段化疗药品对高级别的胶质瘤并不能达到良好的预后效果， 未来胶质瘤领域潜力增长点到底在哪儿？
现阶段胶质瘤流行病学信息及药物治疗方法
胶质瘤领域全球领先药物有哪些？其历史销售走势及综合性顶级投行未来5年预测？
胶质瘤领域中国重点公司及其注册申报情况
6个胶质瘤项目的2022年顶级投行销量预测
灵麦独家签约项目推送，可帮您免费对接
Only two drugs? - Historic and future sales forecast of Glioma
This week Lingmed shares with you a research article on Glioma
A glioma is a type of tumor that starts in the brain or spine. It is called a glioma because it arises from glial cells,including Glioblastoma Multiforme (GBM), Astrocytomas, Oligodendrogliomas and Ependymomas. GBM is the the most common primary brain tumor among adults with increasingly high incidence, especially among the elderly population. However, current chemotherapeutics cannot achieve great prognosis effect for advanced Glioma. What are the future promising growth drivers in the field of Glioma？
The Epidemiology information and treatment regimen for Glioma
The historic sales and consensus sales forecast for global key drugs
The leading Chinese companies and their registraiton information
2022 sales forecast of 6 pormising assets by top Investment Bank
Lingmed exclusive asset opportunities looking for Chinese partners
想要下载完整报告?
请登录 www.lingmed.net/reports
或点击下方“阅读原文”马上下载
